Publications by authors named "T Rokkas"
Background: Helicobacter pylori infection causes gastritis, peptic ulcers, and gastric cancer. The infection is typically acquired in childhood and persists throughout life. The major impediment to successful therapy is antibiotic resistance.
View Article and Find Full Text PDFOvercoming the effects of increasing antimicrobial resistance on therapy.
Expert Rev Gastroenterol Hepatol
November 2024
Introduction: Resistance to the antibiotics used to treat () has risen to alarming levels worldwide emphasizing the need to reconsider the approach to therapy generally and to reconsider whether to continue use of many previously highly effective treatment regimens.
Areas Covered: This review covers current aspects management of the response to the effects of antimicrobial resistance on H. pylori therapy.
Article Synopsis
- Recent studies on potassium-competitive acid blockers (P-CABs) for treating Helicobacter pylori infections reveal a lack of network meta-analysis (NMA) comparing different P-CAB-based treatment regimens for their effectiveness and safety.
- A Bayesian NMA was conducted involving 25 randomized controlled trials with over 7,600 patients, comparing P-CAB and PPI therapies across dual, triple, and quadruple strategies.
- The results indicated that P-CAB dual therapy was the most effective treatment with the best safety profile, highlighting its advantage over traditional methods, particularly in addressing issues like clarithromycin resistance.
Background: Adherence to Helicobacter pylori (H. pylori) eradication treatment is a cornerstone for achieving adequate treatment efficacy.
Objective: To determine which factors influence compliance with treatment.
Article Synopsis
- This study evaluates the effectiveness and safety of various treatments for moderate to severe ulcerative colitis (UC) using a systematic review and network meta-analysis of randomized controlled trials (RCTs).
- Researchers analyzed data from 20 RCTs involving 7660 patients to determine which treatments achieved the best clinical remission rates during maintenance therapy.
- Findings indicate that upadacitinib (30 mg/day) and etrasimod (2 mg/day) are the most effective for different patient treatment approaches, while tofacitinib (10 mg) and infliximab (3.5 mg/Kg Q8W) offer the best overall efficacy-safety profiles.